Trial Profile
A Randomized, Double-Blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs VAK 694 (Primary) ; Fluticasone propionate
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 24 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Apr 2012 Actual patient number is 35 as reported by ClinicalTrials.gov.
- 01 Sep 2010 Planned end date changed from 1 Nov 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.